On April 25, 2025, NKGen Biotech, Inc. entered into a letter agreement with Kepos Alpha Master Fund to exercise 555,555 warrants, resulting in the issuance of 2,593,775 shares of common stock, fulfilling cash obligations with additional shares instead of cash. The exercise price for the additional shares was set at $0.25 each.